6 research outputs found
Vocal cord paralysis during the treatment of mantle cell lymphoma with vincristine
Case description We present a case of a seventy-eight year-old man who developed vocal cord paralysis without any sign of peripheral neuropathy during the treatment of Mantle Cell Lymphoma. He first presented in 2008 with a few bilateral small inguinal lymph nodes. Inguinal lymph node biopsy demonstrated Mantle Cell Lymphoma. Flow cytometry studies of peripheral blood and bone marrow cells were compatible with Mantle Cell Lymphoma. R-CHOP chemotherapy triweekly (Rituximab; Cyclophosphamide; Adriamycin; Vincristine; and Methylprednisolone) was planned. At the end of the second cycle, the patient complained of hoarseness without any symptoms of dysphagia or odynophagia. Direct flexible laryngoscopy showed bilateral vocal cord paralysis. Vincristine was discontinued and the patient's voice gradually resolved in about 4 months. Conclusion Vincristine may cause peripheral, autonomic and cranial neuropathies. However cranial nerve involvement is quite uncommon
Supplementary Material for: Progression of Coronary Artery Calcification in Living Kidney Donors: A Follow-Up Study
<p><b><i>Background:</i></b> Data on the long-term mortality and
morbidity of living kidney donors are scarce. In the general population,
coronary artery calcification (CAC) and progression of CAC are
predictors of future cardiac risk. We conducted a study to determine the
progression of CAC in renal transplant donors. <b><i>Methods:</i></b>
We used multidetector computed tomography to examine CAC in 75 former
renal transplant donors. A baseline and a follow-up scan were performed
and changes in CAC scores were evaluated in each subject individually to
calculate the incidence of CAC progression. <b><i>Results:</i></b>
Baseline CAC prevalence was 16% and the mean CAC score was 5.3 ± 25.8.
At the follow-up scan that was performed after an average of 4.8 ± 0.3
years, CAC prevalence increased to 72% and the mean CAC score to 12.5 ±
23.4. Progression of the individual CAC score was found between 18.7 and
26.7%, depending on the method used to define progression. In patients
with baseline CAC, the mean annualized rate of CAC progression was 2.1.
Presence of hypertension, high systolic blood pressure and an increase
in BMI were the determinants of CAC progression. <b><i>Conclusions:</i></b> The rate of CAC progression does not seem to be high in carefully selected donors.</p